Recombinant Proteins
Modified or manipulated proteins encoded by recombinant DNA and suitable for a variety of purposes including the modification of gene sequences, mass protein production, and the manufacture of commercial products.
Conjugué
- (21)
À utiliser avec (application)
- (16)
- (16)
- (5)
- (16)
Forme
- (21)
Recombinant
- (21)
Espèces
- (1)
Keyword Search:
peprogmp
Effacer toutes les sélections
Résultats de la recherche filtrée
Les produits de certains de nos fournisseurs ne s'affichent pas dans les résultats de la recherche filtrée. Veuillez
supprimer tous les filtres
pour voir ces produits.
1
–
15
de
19
résultats
| Numéro d’adhésion | P01133 |
|---|---|
| Séquence | NSDSECPLSH DGYCLHDGVC MYIEALDKYA CNCVVGYIGE RCQYRDLKWW ELR |
| Type de produit | Protein |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of mouse Balb/c 3T3 cells. PeproGMP Recombinant Human EGF has been tested against the WHO standard NIBSC 91/530. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human EGF |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | EGF |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 6.2 kDa |
| Format | Lyophilized |
| Activité | Determined by the proliferation of mouse Balb/c 3T3 cells. PeproGMP Recombinant Human EGF has been tested against the WHO standard NIBSC 91/530. Find the International Unit (IU) value <a href='https://www.thermofisher.com/us/en/home/life-science/cell-culture/cell-culture-learning-center/recombinant-protein-information/international-units.html'>here</a>. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 1950 |
| Méthode de purification | Purified |
| Symbole de gène(s) | EGF |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | AI790464; beta-urogastrone; EGF; Epidermal growth factor; epidermal growth factor (beta-urogastrone); epidermal growth factor precursor; H-EGF; HOMG4; Pro-epidermal growth factor; Pro-epidermal growth factor precursor (EGF); sb:eu639; URG; Urogastrone |
| Numéro d’adhésion | P15018 |
|---|---|
| Séquence | SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK LGCQLLGKYK QIIAVLAQAF |
| Concentration en endotoxines | <0.1 EU/ μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of TF-1 cells. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human LIF |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | LIF |
| À utiliser avec (application) | Functional Assay |
| État réglementaire | RUO |
| Poids moléculaire | 19.7 kDa |
| Format | Lyophilized |
| Activité | Determined by the proliferation of TF-1 cells. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3976 |
| Formule | protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | CDF; cholinergic differentiation factor; cholinergic neuronal differentiation factor; d factor; DIA; differentiation inhibitory activity; differentiation-inducing factor; differentiation-stimulating factor; Emfilermin; hepatocyte-stimulating factor III; HILDA; human interleukin in DA cells; leukemia inhibitory factor; leukemia inhibitory factor (cholinergic differentiation factor); LIF; Melanoma-derived LPL inhibitor; MLPLI; myeloid leukaemia inhibitory factor |
| Numéro d’adhésion | P21583 |
|---|---|
| Séquence | MEGICRNRVT NNVKDVTKLV ANLPKDYMIT LKYVPGMDVL PSHCWISEMV VQLSDSLTDL LDKFSNISEG LSNYSIIDKL VNIVDDLVEC VKENSSKDLK KSFKSPEPRL FTPEEFFRIF NRSIDAFKDF VVASETSDCV VSSTLSPEKD SRVSVTKPFM LPPVA |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of TF-1 cells. PeproGMP Recombinant Human SCF has been tested against the WHO standard NIBSC 91/682. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human SCF |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | SCF |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 18.4 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 4254 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | 710-712; blz; c-Kit ligand; Clo; cloud gray; Con; contrasted; CSF; DCUA; DFNA69; DKFZp686F2250; familial progressive hyperpigmentation 2; FPH2; FPHH; Gb; grizzle-belly; hematopoietic growth factor KL; H-SCF; Kit ligand; Kitl; Kitlg; kit-ligand; KL-1; Mast cell growth factor; MGF; M-SCF; Processed kit ligand; SCF; SF; SHEP7; sKITLG; Sl; SLF; Soluble KIT ligand; Steel factor; steel factor/kit ligand; stem cell factor; stem cell factor KL-1; stem cell factor, CSF |
| Numéro d’adhésion | P08476 |
|---|---|
| Séquence | GLECDGKVNI CCKKQFFVSF KDIGWNDWII APSGYHANYC EGECPSHIAG TSGSSLSFHS TVINHYRMRG HSPFANLKSC CVPTKLRPMS MLYYDDGQNI IKKDIQNMIV EECGCS |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of mouse MPC-11 cells. PeproGMP Recombinant Human Activin A has been tested against the WHO standard NIBSC 91/626. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human Activin A |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | Activin A |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 26 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3624 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | activin A; activin beta-A chain; BMP7; BMP-7; Bone morphogenetic protein 7; EDF; Eptotermin alfa; erythroid differentiation factor; erythroid differentiation protein; follicle-stimulating hormone-releasing protein; FRP; FSH-releasing protein; INHB; Inhba; inhibin B subunit; inhibin beta A chain; inhibin beta A protein; inhibin beta A subunit; inhibin beta-A; inhibin beta-A-subunit; inhibin beta-subunit; inhibin subunit beta A; inhibin, beta A; inhibin, beta A (activin A, activin AB alpha polypeptide); Inhibin, beta-1; OP1; OP-1; Osteogenic protein 1; unnamed protein product |
| Numéro d’adhésion | P12644 |
|---|---|
| Séquence | MKKNKNCRRH SLYVDFSDVG WNDWIVAPPG YQAFYCHGDC PFPLADHLNS TNHAIVQTLV NSVNSSIPKA CCVPTELSAI SMLYLDEYDK VVLKNYQEMV VEGCGCR |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human BMP-4 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | BMP4 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 24.2 kDa |
| Format | Lyophilized |
| Activité | Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 652 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | BMP; BMP2B; BMP-2B; Bmp2b1; Bmp2b-1; Bmp4; Bmp-4; BOMPR4A; Bone morphogenetic protein; Bone morphogenetic protein 2B; bone morphogenetic protein 4; bone morphogenetic protein 4 preproprotein; DVR4; Dvr-4; MCOPS6; OFC11; ZYME |
| Numéro d’adhésion | Q9HBE4 |
|---|---|
| Séquence | MQDRHMIRMR QLIDIVDQLK NYVNDLVPEF LPAPEDVETN CEWSAFSCFQ KAQLKSANTG NNERIINVSI KKLKRKPPST NAGRRQKHRL TCPSCDSYEK KPPKEFLERF KSLLQKMIHQ HLSSRTHGSE DS |
| Concentration en endotoxines | <0.1 EU/ μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of ANBL-6 cells. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-21 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | IL-21 |
| À utiliser avec (application) | Functional Assay |
| État réglementaire | RUO |
| Poids moléculaire | 15.4 kDa |
| Format | Lyophilized |
| Activité | Determined by the proliferation of ANBL-6 cells. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 59067 |
| Formule | protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | CVID11; C x 2; il 21; IL21; IL-21; ILN; Interleukin; interleukin 21; Interleukin21; interleukin-21; interleukin-21 isoform; porcine interleukin-21; Za11 |
| Numéro d’adhésion | P04085 |
|---|---|
| Séquence | SIEEAVPAVC KTRTVIYEIP RSQVDPTSAN FLIWPPCVEV KRCTGCCNTS SVKCQPSRVH HRSVKVAKVE YVRKKPKLKE VQVRLEEHLE CACATTSLNP DYREEDTGRP RESGKKRKRK RLKPT |
| Concentration en endotoxines | <0.1 EU/ μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of mouse Balb/c 3T3 cells. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human PDGF-AA |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | PDGF-AA |
| À utiliser avec (application) | Functional Assay |
| État réglementaire | RUO |
| Poids moléculaire | 28.5 kDa |
| Format | Lyophilized |
| Activité | Determined by the proliferation of mouse Balb/c 3T3 cells. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 5154 |
| Formule | protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | H-PDGF-AA; PDGF A-chain; PDGF subunit A; PDGF1; PDGF-1; Pdgfa; PDGF-A; PDGFACP; platelet derived growth factor subunit A; platelet derived growth factor, alpha; Platelet-derived growth factor A chain; platelet-derived growth factor A-chain; platelet-derived growth factor alpha chain; platelet-derived growth factor alpha polypeptide; Platelet-derived growth factor subunit A; Rpa1 |
| Numéro d’adhésion | P13232, P16871 |
|---|---|
| Séquence | DCDIEGKDGK QYESVLMVSI DQLLDSMKEI GSNCLNNEFN FFKRHICDAN KEGMFLFRAA RKLRQFLKMN STGDFDLHLL KVSEGTTILL NCTGQVKGRK PAALGEAQPT KSLEENKSLK EQKKLNDLCF LKRLLQEIKT CWNKILMGTK EH |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of mouse 2E8 cells. PeproGMP Recombinant Human IL-7 ha been tested against the WHO standard NIBSC 90/530. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-7 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | IL-7 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 17.4 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3574, 3575 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | A630026I06Rik; H-IL-7; hlb368; IL7; Il-7; ILN; Interleukin; interleukin 7; Interleukin7; interleukin-7; M-IL-7 |
| Numéro d’adhésion | P60568 |
|---|---|
| Séquence | MAPTSSSTKK TQLQLEHLLL DLQMILNGIN NYKNPKLTRM LTFKFYMPKK ATELKHLQCL EEELKPLEEV LNLAQSKNFH LRPRDLISNI NVIVLELKGS ETTFMCEYAD ETATIVEFLN RWITFAQSII STLT |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of mouse CTLL-2 cells. PeproGMP Recombinant Human IL-2 ha been tested against the WHO standard NIBSC 86/500. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-2 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | IL-2 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 15.5 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3558 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | aldesleukin; cytokine; H-IL-2; il 2; Il2; Il-2; ILN; Interleukin; interleukin 2; interleukin 2 precursor; interleukin 2 variant IL2delta2; Interleukin2; Interleukin-2; interleukin-2 precursor; interleukin-2 precursor protein; interleukin-2; interleukin 2; Involved in regulation of T cell clonal expansion; involved in regulation of T-cell clonal expansion; lymphokine; M-IL-2; patial sequence of Interleukin-2; POIL2; porcine Interleukin 2; T cell growth factor; T-cell growth factor; T-cell growth factor (TCGF); TCGF |
| Numéro d’adhésion | P15692 |
|---|---|
| Séquence | APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR |
| Concentration en endotoxines | <0.1 EU/ μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of HUVECs. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human VEGF-165 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | VEGF-165 |
| À utiliser avec (application) | Functional Assay |
| État réglementaire | RUO |
| Poids moléculaire | 38.2 kDa |
| Format | Lyophilized |
| Activité | Determined by the proliferation of HUVECs. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 7422 |
| Formule | protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | H-VEGF-165; MVCD1; M-VEGF-165; vascular endothelial growth factor 165 b; vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular permeability factor; VEGF; VEGF164; VEGF165; Vegfa; VEGF-A; VPF |
| Numéro d’adhésion | P40933 |
|---|---|
| Séquence | MNWVNVISDL KKIEDLIQSM HIDATLYTES DVHPSCKVTA MKCFLLELQV ISLESGDASI HDTVENLIIL ANNSLSSNGN VTESGCKECE ELEEKNIKEF LQSFVHIVQM FINTS |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of CTLL-2 cells. PeproGMP Recombinant Human IL-15 ha been tested against the WHO standard NIBSC 95/554. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-15 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | IL-15 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 12.9 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3600 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | AI503618; il 15; Il15; IL-15; ILN; Interleukin; interleukin 15; Interleukin15; interleukin-15; MGC9721; M-IL-15 |
| Numéro d’adhésion | P08700 |
|---|---|
| Séquence | APMTQTTSLK TSWVNCSNMI DEIITHLKQP PLPLLDFNNL NGEDQDILME NNLRRPNLEA FNRAVKSLQN ASAIESILKN LLPCLPLATA APTRHPIHIK DGDWNEFRRK LTFYLKTLEN AQAQQTTLSL AIF |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by the proliferation of TF-1 cells. PeproGMP Recombinant Human IL-3 ha been tested against the WHO standard NIBSC 91/510. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-3 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | IL-3 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 15 kDa |
| Format | Lyophilized |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3562 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | BP/BPA; BPA; Colony stimulating factor multiple; colony-stimulating factor, multiple; Csfmu; Eo-CSF; HCGF; hematopoietic growth factor; Il3; Il-3; ILN; Interleukin; interleukin 3; Interleukin 3 (colony stimulating factor; Interleukin3; interleukin-3; Mast cell growth factor; mast-cell growth factor; MCGF; MGC79398; MGC79399; MGF; Multi CSF; MULTI-CSF; Multilineage colony stimulating factor; multilineage-colony-stimulating factor; multiple); multipotential colony-stimulating factor; P cell stimulating factor; P-cell stimulating factor; P-cell-stimulating factor; PCSA; PSF |
| Numéro d’adhésion | P40225 |
|---|---|
| Séquence | SPAPPACDLR VLSKLLRDSH VLHSRLSQCP EVHPLPTPVL LPAVDFSLGE WKTQMEETKA QDILGAVTLL LEGVMAARGQ LGPTCLSSLL GQLSGQVRLL LGALQSLLGT QLPPQGRTTA HKDPNAIFLS FQHLLRGKVR FLMLVGGSTL CVRRAPPTTA VPSRTSLVLT LNEL |
| Type de produit | Protein |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human TPO (Thrombopoietin) |
| Forme | Lyophilized |
| Nom usuel | Thrombopoietin |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 18.6 kDa |
| Conditions de stockage | -20°C or -80°C if preferred |
| Activité | Determined by its ability to stimulate human MO7e cell proliferation. PeproGMP Recombinant HumanTPO has been tested against the WHO standard NIBSC 03/124. Find the International Unit (IU) value <a href='https://www.thermofisher.com/us/en/home/life-science/cell-culture/cell-culture-learning-center/recombinant-protein-information/international-units.html'>here</a>. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 7066 |
| Méthode de purification | Purified |
| Symbole de gène(s) | THPO |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | C-mpl ligand; Megakaryocyte colony-stimulating factor; megakaryocyte growth and development factor; megakaryocyte stimulating factor; Mgdf; MKCSF; ML; MPL ligand; Mpllg; MSA; Myeloproliferative leukemia virus oncogene ligand; prepro-thrombopoietin; TDH2A; THCYT1; THPO; Thrombopoietin; thyroid microsomal antigen; thyroid peroxidase; thyroperoxidase; Tpo; TPX |
| Numéro d’adhésion | P05231 |
|---|---|
| Séquence | PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR KETCNKSNMC ESSKEALAEN NLNLPKMAEK DGCFQSGFNE ETCLVKIITG LLEFEVYLEY LQNRFESSEE QARAVQMSTK VLIQFLQKKA KNLDAITTPD PTTNASLLTK LQAQNQWLQD MTTHLILRSF KEFLQSSLRA LRQM |
| Type de produit | Protein |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human IL-6 |
| Forme | Lyophilized |
| Nom usuel | IL-6 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 20.9 kDa |
| Conditions de stockage | -20°C or -80°C if preferred |
| Activité | Determined by the proliferation of mouse 7TD1 cells. PeproGMP Recombinant Human IL-6 has been tested against the WHO standard NIBSC 89/548. Find the International Unit (IU) value <a href='https://www.thermofisher.com/us/en/home/life-science/cell-culture/cell-culture-learning-center/recombinant-protein-information/international-units.html'>here</a>. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3569 |
| Méthode de purification | Purified |
| Symbole de gène(s) | Il6 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | B-cell differentiation factor; B-cell hybridoma growth factor; B-cell stimulatory factor 2; BSF2; BSF-2; CDF; CHIL-6; CTL differentiation factor; cytokine; HGF; H-IL-6; HSF; hybridoma growth factor; Ifnb2; IFN-beta-2; Il6; IL-6; ILg6; ILN; interferon beta-2; Interleukin; interleukin 6; Interleukin 6 (interferon, beta 2); interleukin 6 precursor; interleukin BSF-2; interleukin HP-1; Interleukin6; Interleukin-6; interleukin-6 precursor; interleukin-6 protein; M-IL-6; prointerleukin 6; R-IL-6 |
| Numéro d’adhésion | Q02297 |
|---|---|
| Séquence | SHLVKCAEKE KTFCVNGGEC FMVKDLSNPS RYLCKCPNEF TGDRCQNYVM ASFYKHLGIE FMEAE |
| Concentration en endotoxines | ≤0.1 EU/μg |
| Pureté ou qualité | ≥ 98% by SDS-PAGE gel and HPLC analyses. |
| Activité biologique | Determined by proliferation of human MCF-7 cells. |
| Conjugué | Unconjugated |
| Nom | PeproGMP™ Human Heregulin beta-1 |
| Forme | Lyophilized |
| Contenu et stockage | -20°Cor to +80°C if preferred |
| Nom usuel | HRG beta-1 |
| À utiliser avec (application) | Control,Western Blot Control,Bioactivity |
| État réglementaire | GMP |
| Poids moléculaire | 7.5 kDa |
| Format | Lyophilized |
| Activité | Determined by proliferation of human MCF-7 cells. |
| Système d’expression | E. coli |
| Identification génétique (Entrez) | 3084 |
| Formule | Protein with no preservative |
| Recombinant | Recombinant |
| Alias de gène | 6030402G23Rik; acetylcholine receptor-inducing activity; ARIA; Breast cancer cell differentiation factor p45; D230005F13Rik; GGF; GGF2; GGFII; Glial growth factor; glial growth factor 2; heregulin; heregulin, alpha (45kD, ERBB2 p185-activator); Hgl; HRG; HRG1; HRGA; HRGalpha; MST131; MSTP131; NDF; Neu differentiation factor; neuregulin 1; neuregulin 1 type III beta 3; Neuregulin-1; Nrg1; NRG1-IT2; Pro-neuregulin-1, membrane-bound isoform; pro-NRG1; sensory and motor neuron derived factor; Sensory and motor neuron-derived factor; SMDF; type I neuregulin 1; type III neuregulin 1 |